http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5070571-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ad58d3c0b071069a8ee0cb8c8ba2e8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7016
filingDate 1999-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12bb5ce04900dcd26a3b491144e935df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d47053ccd59d869cccc677b633aa6fcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06614885179cc881322fe8aff4e698b2
publicationDate 2001-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CO-5070571-A1
titleOfInvention PHARMACEUTICAL MOXIFLOXACINE PREPARATION
abstract Pharmaceutical preparation for oral administration containing moxifloxacin or a salt and / or hydrate thereof, at least one dry binder, at least one disintegration aid, and at least one lubricating agent, characterized in that the preparation contains 2.5% at 25% lactose Pharmaceutical preparation for oral administration according to claim 1, characterized in that the preparation contains, based on an individual dosage, 50 to 800 mg of moxifloxacin or its salts and / or hydrates. Pharmaceutical preparation for oral administration according to claim 1 or 2, characterized in that the dry binder is microcrystalline cellulose. Pharmaceutical preparation for oral administration according to one of claims 1 to 3, characterized in that the disintegration aid is croscarmellose sodium. Pharmaceutical preparation for oral administration according to any one of claims 1 to 4, characterized in that the lubricating agent is magnesium stearate.
priorityDate 1998-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503137
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496863
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449454525
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553385
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84571
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322677

Total number of triples: 36.